Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.

• Klíčová slova
• Artificial intelligence, Biomarkers, Early detection, Omics, Pancreatic cancer,
• MeSH
• časná detekce nádoru * metody   MeSH
• duktální karcinom slinivky břišní diagnóza   genetika   MeSH
• genomika metody   MeSH
• lidé MeSH
• nádorové biomarkery * MeSH
• nádory slinivky břišní * diagnóza   genetika   MeSH
• umělá inteligence * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• nádorové biomarkery * MeSH